NCT01469169 - Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 19, 2012

Primary Completion Date

December 26, 2014

Study Completion Date

December 14, 2016

Conditions

Hypertension, Pulmonary

Interventions

DRUG

Iloprost (Ventavis inhaled, BAYQ6256)

2.5 μg or 5.0 μg BAYQ6256 per inhalation session (Inhalation session is to be conducted 6 to 9 times per day with dosing intervals of at least 2 hours.)

Trial Locations (18)

466-8560

Nagoya

467-8602

Nagoya

830-0011

Kurume

078-8510

Asahikwa

650-0017

Kobe

216-8511

Kawasaki

980-8574

Sendai

901-0243

Tomigusuku

113-8655

Bunkyo-ku

104-8560

Chuoku

181-8611

Mitaka

143-8541

Ōta-ku

160-8582

Shinjuku-ku

162-8655

Shinjuku-ku

646-8558

Tanabe

755-8505

Ube

260-8677

Chiba

770-8503

Tokushima